Modules
Modules
The Immune System
The Immune System
Overview/Key Objectives
The Immune System
Components of the Immune System
The Innate vs. Adaptive Immune Response
Inflammation
Adaptive Immunity – Humoral and Cellular Immunity
Activated vs. Anergic Immune Functionality
References
Assessment Questions
Cancer and the Immune System: History and Theory
Cancer and the Immune System: History and Theory
Overview/Key Objectives
Brief History of Cancer Immunotherapy Approaches and Theories
A Hallmark of Cancer – Evasion of Immune Destruction
Immuno-oncology Theories – Immunoediting and Immune Surveillance
Cancer-Immunity Cycle
References
Assessment Questions
Clinical Indications
Clinical Indications
Overview/Key Objectives
Breast Cancer
Melanoma
Colorectal Cancer
Gastric/Gastroesophageal Junction Cancer
Lung Cancer
Bladder Cancer
Kidney Cancer
Prostate Cancer
Cervical Cancer
B-Cell Non-Hodgkin Lymphoma
Classical Hodgkin Lymphoma
Acute Lymphoblastic Leukemia
Anaplastic Large-Cell Lymphoma
Multiple Myeloma
Merkel Cell Carcinoma
Summary
References
Assessment Questions
Immune System Signaling Pathways
Immune System Signaling Pathways
Overview/Key Objectives
T Cell Signaling
Natural Killer Cell Signaling
B7 Family of Ligands
Inflammation
Inhibitory Signaling Pathways
References
Assessment Questions
Immunotherapies
Immunotherapies
Overview/Key Objectives
Non-targeted (Non-specific) Immunotherapies
Targeted Immunotherapies: Monoclonal Antibodies, Checkpoint Inhibitors, Therapeutic Vaccines
Targeted Immunotherapies: Adoptive Cell Therapies, Oncolytic Virus Therapy
Single vs. Combination Immunotherapies
References
Immunotherapy: Adverse Events
Immunotherapy: Adverse Events
Overview/Key Objectives
Cardiovascular
Dermatologic
Endocrine
Endocrine cont
Gastrointestinal
Cardiovascular
Pulmonary
Renal
Cardiovascular
Neurologic Conditions
Summary
References
Assessment Questions
Adverse Events
Adverse Events
Overview/Key Objectives
Rituximab
Trastuzumab
Alemtuzumab
Ibritumomab Tiuxetan
Cetuximab
Bevacizumab
Panitumumab
Recombinant HPV vaccines
Ofatumumab
Sipuleucel-T
Peginterferon alfa-2b
Ipilimumab
Brentuximab vedotin
Pertuzumab
Ado-trastuzumab emtansine
Obinutuzumab
Blinatumomab
Nivolumab
Pembrolizumab
Ramucirumab
Talimogene laherparepvec
Daratumumab
Elotuzumab
Atezolizumab
References
Assessment Questions
Quizzes
Tumor Boards
Videos
About
Visit Healio.com
Modules
The Immune System
Overview/Key Objectives
The Immune System
Components of the Immune System
The Innate vs. Adaptive Immune Response
Inflammation
Adaptive Immunity – Humoral and Cellular Immunity
Activated vs. Anergic Immune Functionality
References
Assessment Questions
Cancer and the Immune System: History and Theory
Overview/Key Objectives
Brief History of Cancer Immunotherapy Approaches and Theories
A Hallmark of Cancer – Evasion of Immune Destruction
Immuno-oncology Theories – Immunoediting and Immune Surveillance
Cancer-Immunity Cycle
References
Assessment Questions
Clinical Indications
Overview/Key Objectives
Breast Cancer
Melanoma
Colorectal Cancer
Gastric/Gastroesophageal Junction Cancer
Lung Cancer
Bladder Cancer
Kidney Cancer
Prostate Cancer
Cervical Cancer
B-Cell Non-Hodgkin Lymphoma
Classical Hodgkin Lymphoma
Acute Lymphoblastic Leukemia
Anaplastic Large-Cell Lymphoma
Multiple Myeloma
Merkel Cell Carcinoma
Summary
References
Assessment Questions
Immune System Signaling Pathways
Overview/Key Objectives
T Cell Signaling
Natural Killer Cell Signaling
B7 Family of Ligands
Inflammation
Inhibitory Signaling Pathways
References
Assessment Questions
Adverse Events
Overview/Key Objectives
Rituximab
Trastuzumab
Alemtuzumab
Ibritumomab Tiuxetan
Cetuximab
Bevacizumab
Panitumumab
Recombinant HPV vaccines
Ofatumumab
Sipuleucel-T
Peginterferon alfa-2b
Ipilimumab
Brentuximab vedotin
Pertuzumab
Ado-trastuzumab emtansine
Obinutuzumab
Blinatumomab
Nivolumab
Pembrolizumab
Ramucirumab
Talimogene laherparepvec
Daratumumab
Elotuzumab
Atezolizumab
References
Assessment Questions
Quizzes
Tumor Boards
Videos
About
Login
Register
My Account
My Curriculum
Log Out
Visit Healio.com
Toggle navigation
Healio
Hematology/Oncology
Learn Immuno-Oncology
Videos
VIDEOS
Immuno Oncology Videos
Robert Andtbacka, MD, discusses currently approved immunotherapeutic agents in melanoma.
Return to Video Contents
×
Close
Notice